PVR and Nectin-2 Blockade Reactivates Macrophage Anti-Tumor Functions in Cervical Cancer

Despite vaccination programs, cervical cancer remains a major health burden. Anti-PD-1 immunotherapy with pembrolizumab improved progression-free survival from 20% to 50% in advanced disease — yet many patients remain resistant, calling for new immune checkpoint targets. One promising candidate is the TIGIT–PVRL axis: TIGIT, expressed by regulatory and exhausted T cells, binds its ligands PVR and Nectin-2 to maintain immunosuppression in the tumor microenvironment.

In a new study from the Cancer Research Center of Marseille (Gorvel et al., bioRxiv preprint), researchers explored the other side of this axis — the myeloid compartment. Showing that PVR and Nectin-2 are highly expressed on tumor cells and tumor-associated macrophages (TAMs) across cervical tumor subsets, they tested whether blocking these ligands could lift immunosuppression, combining CyTOF immunophenotyping, high-throughput confocal imaging, 3D co-culture models, and autologous tumor–PBMC co-cultures under flow using MIVO® millifluidics.

Key Findings

  • Macrophage repolarization. Anti-PVR and anti-Nectin-2 antibodies shifted macrophages from an immunosuppressive, M2-like profile towards an inflammatory phenotype.
  • Phagocytosis restored. PVR — described as a secondary “don’t eat me” signal — was shown to sustain tumor escape: its blockade restored macrophage-mediated phagocytosis of cervical tumor cells.
  • Tumor growth controlled in 2D and 3D. The dual blockade reduced tumor growth in co-culture models, suggesting that complete blockade of TIGIT–ligand interactions reinvigorates anti-tumor immunity.
  • Immune recruitment enhanced under flow. In a preclinical autologous model pairing patient cervical tumor cells with circulating PBMCs in the MIVO® system, anti-PVR/Nectin-2 treatment improved immune cell recruitment towards the tumor.

Take-Home Message

This study provides a first proof of concept that targeting the TIGIT–PVRL axis from the myeloid side — through dual PVR/Nectin-2 blockade — restores macrophage inflammatory functions and cervical tumor growth control in vitro and ex vivo. Such macrophage-targeting approaches could complement T cell-directed immunotherapies, and complex millifluidic co-culture models offer a relevant platform to test them with human autologous cells.

Note: this work is a preprint and has not yet been peer-reviewed.

Reference: Diallo OM, Boucherit N, Fernez T, Barry AO, Billion E, Rouvière MS, et al. PVR and Nectin-2 blockade trigger macrophage anti-tumor functions, promote immune cell recruitment and prevent cervical tumor growth. bioRxiv. 2026. https://doi.org/10.64898/2026.01.30.702794

Download the paper
All Resources

Never stop learning!

Check publications from the team, protocols, and useful information to boost your research and get into organ on chip technology!

Knowledge Hub